Oral fulvestrant as the next standard of care for ER+ metastatic breast cancer
Official title: Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer
Funded at Veramorph, LLC · NIH-11457452 · Data updated 2026-11-12
A new oral formulation of fulvestrant is being tested to help people with ER-positive metastatic breast cancer have a longer, better-tolerated response to treatment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veramorph, LLC NIH-funded |
| Lab location | 1 site (Norwood, United States) |
| Project start | September 10, 2025 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $935,236 |
| NIH project number | 4R44CA306533-02 |
| Project ID | NIH-11457452 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with ER-positive metastatic breast cancer eligible for fulvestrant-based therapy.
✕Less likely to help
Patients whose cancer does not respond to SERD therapy or cannot tolerate oral medications may not benefit.
What this research studies
This project aims to turn fulvestrant into an effective oral therapy using VeraMorph’s DPOD delivery to improve drug exposure and potency. It focuses on patients with estrogen receptor–positive breast cancer whose cancer has spread, seeking to extend the time before progression while maintaining quality of life. The study will collect pharmacokinetic data and safety information to support a potential shift from injections to an oral daily regimen. If successful, patients could experience easier administration, better adherence, and longer control of disease.
Why it matters
Potential benefit: If successful, patients may have a more convenient and potentially more effective treatment option that delays progression.
How similar studies have gone: Prior studies show fulvestrant is effective but limited by injectable administration; oral delivery remains investigational with promising pharmacokinetics in early work.
Where this research is happening
-
Veramorph, LLC
Norwood, United States Active
Researchers
- Principal investigator: Godfrin, Paul Douglas — Veramorph, LLC
- Study coordinator: Godfrin, Paul Douglas
Related research
Other NIH-funded projects on the same topics.
-
Understanding FGFR1-amplified breast cancer to overcome endocrine resistance
This project explores why a type of breast cancer with FGFR1 changes stops responding to hormone therapy and looks for new combination treatments that may help patients live longer.
-
Fit2ThriveMB: A digital activity program to help people with metastatic breast cancer feel better and stay active
A digital, at-home physical activity program designed for people with metastatic breast cancer to improve quality of life and daily functioning.
-
Acupuncture to ease symptoms for people with metastatic breast cancer
A clinical trial will test whether weekly acupuncture for 12 weeks can reduce symptom burden for people with metastatic breast cancer who are on standard therapy.
-
Predicting end-of-life timing to guide better care for metastatic breast cancer
A clinician-facing project tests a breast cancer prognostic tool in everyday oncology care to help guide conversations and timely hospice referrals for patients nearing the end of life.
-
Combining antibody-drug conjugates with mechanism-based therapies to treat metastatic triple-negative breast cancer
A research team is testing new combination strategies that pair antibody-drug conjugates with other targeted treatments to better treat metastatic triple-negative breast cancer.
-
Personalized therapies for metastatic breast cancer using patient-derived models
Doctors and researchers are testing how patient-derived tumor models can help find effective treatments for metastatic breast cancer and predict which therapies will work based on molecular clues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.